Panacea Acquisition Corp. Files for $125M IPO
by Matt Cianci on 2020-06-15 at 3:03pm

Last week, Panacea Acquisition Corp. (PANA.U), became the latest biotech-focused SPAC to tap the market with a $125 million IPO. The entity is backed by EcoR1, a biotechnology-focused hedge fund founded in 2013. Panacea is led by EcoR1 founder, Oleg Nodelman, who has been investing in biotechnology companies for over 20 years. The rest of Nodelman’s team has a background with “value-oriented” biotechnology investments—likely having much to do with everyone’s involvement with EcoR1. While value is a rather subjective term these days, it seems apparent the SPAC will prioritize some kind of “value” factor for their target.

In recent years big pharma significantly increased its investments in private biotech companies as they see venture capital as a higher ROI endeavor than traditional R&D. Assuming they’ve made worthy investments, this could mean there are plenty of life sciences startups (and corporate sponsors) looking to go public. Additionally, the team believes they will be able to find a target with a solid risk/reward profile primarily coming from “multiple assets”, rather than relying on a single “shot on goal”. This means they expect to find value beyond just a company’s pipeline + TAM. This could include intellectual property, unreleased products, or partnerships with big pharmaceuticals developers, according to Institutional Investor.

Prior to EcoR1, Oleg Nodelman was a portfolio manager at one of the original biotech hedge funds on Wall Street, Biotechnology Value Fund (BVF), which he left in 2013 to start EcoR1. Perhaps an indication of Oleg’s perception of value, he is on the board of Prothena (PRTA), which has a pipeline of drugs anywhere from the Discovery to Phase II stages. He is a Ukrainian immigrant who grew up with an immunologist and engineer for parents, and has spent much of his professional life in San Francisco where he is involved with local charities.

Oleg’s right-hand-woman and Chief Investment Officer is Caroline Stout. She currently serves as a principal at EcoR1, and prior to that an investment banker serving biotechnology clients. It is interesting to see her board membership includes Neurogene (focused on neurological gene therapy), Accent Therapeutics (epitranscriptomics as an alternative to traditional chemo), and Prevail Therapeutics (gene therapy research for neurodegenerative disorders).

EcoR1 Capital gets its name from the EcoR1 restriction enzyme found in E. coli. These enzymes are found in bacteria and act as defense mechanisms against invading viruses. Technically, the enzyme cuts up the DNA sequence of the virus, which is useful for scientists experimenting with molecular cloning applications like gene therapy.  A quick glance over their venture portfolio shows a handful of gene therapy companies focused on treating cancers neurological disorders—not surprising given leadership’s backgrounds. The fund has seen tremendous success since opening its doors in 2013, returning 34% annually to investors and having to close to new investors after just four years in business.

The deal leaves Panacea with $150M in cash when the $25M FPA is included—an amount that leaves the team with plenty of flexibility for target size. Judging by the name, however, “Panacea” means a ‘universal cure’, so perhaps the team is expecting to swing for the fences with their first deal. The terms seem appropriate given it is a first-time team with a strong resume—24 months and just a 1/3 warrant. For what it’s worth, of the 106 SPAC’s we are tracking that have filed for an IPO and are searching for a target, this is the 11th focused on the life sciences space.

Summary of terms below:

Recent Posts
by Nicholas Alan Clayton on 2024-11-12 at 10:35am

Flagfish Acquisition Corporation (NASDAQ:FFSHU) has filed for a $60 million IPO to give another bite at the apple to a China-based team that last closed a deal in the biotech space. Flagfish Chairman and CEO Matthew Chen also serves in the same role for Flag Ship (NASDAQ:FSHP), which just last month announced a deal with...

by Nicholas Alan Clayton on 2024-11-12 at 8:06am

At the SPAC of Dawn SPACs have been betting on a post-pandemic rebirth in live events over the past few years, but it appears that this boom has fully come to fruition. Event organizer Live Nation (NYSE:LYV) announced yesterday that it just closed its busiest summer concert season ever, bringing in $7.7 billion in revenue...

by Nicholas Alan Clayton on 2024-11-11 at 2:27pm

Hennessy Capital VII (NASDAQ:HVIIU) has filed for a $150 million IPO with competitive terms to give a fresh vehicle to one of the most prolific SPAC teams of the past decade. This team has had a hand in 13 different business combinations dating back to Hennessy I‘s 2015 combination with school bus manufacturer Blue Bird...

by Nicholas Alan Clayton on 2024-11-11 at 8:27am

At the SPAC of Dawn With the US election and a historic stock rally in the rear view, the question now turns to how long this rally will last and SPACs have not been shy so far about trying to take advantage of the good vibes. Two new SPACs filed for IPOs Friday evening and...

by Kristi Marvin on 2024-11-09 at 10:00am

Terms Tracker for the Week Ending November 8, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. This week saw three more SPACs price IPOs along with a slight improvement in IPO trading performance. More importantly, the Presidential election was won decisively,...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved